Cefotaxime

Research use only, not for human use.

Cefotaxime is an inhibitor of penicillin binding protein.

Cefotaxime is an inhibitor of penicillin binding protein.(In Vitro):Cefotaxime exhibits an MIC of 0.0625 mg/L for V. vulnificus CMCP6.(In Vivo):The combination of ciprofloxacin and cefotaxime is more effective in clearing V. vulnificus in vivo than previously used regimens.

Cefotaxime exhibits an MIC of 0.0625 mg/L for V. vulnificus CMCP6.

The combination of ciprofloxacin and cefotaxime is more effective in clearing V. vulnificus in vivo than previously used regimens. Animal Model:Female, specific pathogen free, 8-week-old BALB/c mice.Dosage:30 mg/kg. Administration:IP every 6 h.Result:The viable bacterial counts in liver were lower in mice treated with cefotaxime-plus-ciprofloxacin than in those treated with cefotaxime alone (P<0.001 at 24 h and 48 h, each).

——

Microbiology/Virology

Antifection

Antifection

——

Focus Groups

63527-52-6

455.46

C16H17N5O7S2

>98% (HPLC)

DMSO:91 mg/mL (199.79 mM)

CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1

(6R7R)-3-(acetoxymethyl)-7-((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years